Research Article
Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre
Table 1
Baseline characteristics.
| Clinical parameter | Patient numbers |
| Age (years), mean ± SD | 47.1 (12.2) | Sex | M 39 (29%), F 96 (71%) | Ethnicity | | (i) Caucasian | 89 (66%) | (ii) Black | 27 (20%) | (iii) Asian (Indian) | 2 (2%) | (iv) Asian (oriental) | 2 (2%) | (v) Latino | 6 (4%) | (vi) Mixed | 3 (2%) | Diabetes | 39/134 (29%) | Other MetSy features | 60/134 (45%) | Taking ACE-inhibitor medication | 94/133 (71%) | Fasting BSL (mmol/L), mean ± SD | 6.0 ± 2.7 | Weight (kg), mean ± SD | 117.9 ± 22.0 | BMI (kg/m2), mean ± SD | 41.7 ± 6.6 | Waist circumference (cm), mean ± SD | 124.2 ± 13.6 | Fasting cholesterol (mmol/L), mean ± SD | 4.8 ± 1.4 | Fasting LDL (mmol/L), mean ± SD | 2.7 ± 1.1 | Fasting HDL (mmol/L), mean ± SD | 1.2 ± 0.3 | Fasting triglycerides (mmol/L), mean ± SD | 1.8 ± 1.0 | Fasting insulin (mIU/L), mean ± SD | 136.0 ± 169.0 | HOMA-IR , median (range | 3.6 (2.1–5.9) | ALT (IU/L), mean ± SD | 38.9 ± 30.6 | AST (IU/L), mean ± SD | 35.1 ± 25.2 | GGT (IU/L), mean ± SD | 62.6 ± 74.9 | Fib-4 score , mean ± SD | 1.5 ± 0.7 | Period of 1st IGB placement (months), mean ± SD | 5.8 ± 1.7 | Total number of balloons | One = 135, two = 48, three =20 |
|
|
5–75% interquartile ranges expressed.
|